Sugi Predict

Sugi Predict / Compounds / SCHEMBL3079694

SCHEMBL3079694

SCHEMBL3079694

C#CCCCC(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ CYP1A2 P05177 2/20 0.50
▸ CYP3A4 P08684 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ SLC6A3 Q01959 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.45
▸ HTT P42858 1/20 0.44
▸ EPHX2 P34913 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ NOTUM Q6P988 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5943360 0.95 ALDH1A1 (0.53) ALDH1A1MAPK1L3MBTL1CYP1A2CYP3A4
SCHEMBL25167616 0.94 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1CYP1A2CYP3A4
SCHEMBL29347075 0.94 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1CYP1A2CYP3A4
SCHEMBL29991029 0.94 ALDH1A1 (0.51) ALDH1A1MAPK1L3MBTL1CYP1A2CYP3A4
SCHEMBL3877532 0.90 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL6957056 0.85 ALDH1A1 (0.56) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL3963428 0.84 ALDH1A1 (0.68) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL18673 0.84 ALDH1A1 (0.68) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL12177053 0.84 ALDH1A1 (0.54) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL2926392 0.83 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582722-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2026-03-24 — — US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed
US-20220143195-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2022-05-12 — — US disclosed
US-20220143195-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2022-05-12 — — US disclosed
EP-3924350-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY Nurix Therapeutics, Inc. (US) 2021-12-22 — — EP disclosed
WO-2020167518-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2020-08-20 — — WO disclosed
WO-2020167518-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2020-08-20 — — WO disclosed
US-7795166-B2 Functional group-selective hydrogenation catalyst and functional group-selective hydrogenation method N.E. CHEMCAT CORPORATION (JP) 2010-09-14 — — US disclosed
US-20070155617-A1 FUNCTIONAL GROUP-SELECTIVE HYDROGENATION CATALYST AND FUNCTIONAL GROUP-SELECTIVE HYDROGENATION METHOD N. E. CHEMCAT CORPORATION (JP) 2007-07-05 — — US disclosed
US-20060142315-A1 Substituted biaryl piperazinyl-pyridine analogues NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2006-06-29 — — US disclosed
WO-2004082613-A2 2,4-DIAMINO-5-[5’-SUBSTITUTED-BENZYL] PYRIMIDINES AND 2,4-DIAMINO-6-[5’-SUBSTITUTED-BENZYL] QUINAZOLINES DANA FARBER CANCER INSTITUTE (US) 2004-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 ALDH1A1 3134/4885MAPK1 2484/4885L3MBTL1 1690/4885
US-12582722-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway PSMB2, PSME3, PSMB3 ALDH1A1 4614/4885MAPK1 1571/4885L3MBTL1 1179/4885
US-20220143195-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY CBL, XIAP, BTK ALDH1A1 4160/4885MAPK1 1989/4885L3MBTL1 857/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 ALDH1A1 3173/4885MAPK1 2490/4885L3MBTL1 1923/4885
US-20060142315-A1 Substituted biaryl piperazinyl-pyridine analogues DHFR, DPYD, DLD ALDH1A1 204/4885MAPK1 4669/4885L3MBTL1 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.